- Home
- WNW vs XRTX Comparison
WNW vs XRTX Comparison
Compare WNW & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WNW | XRTX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.2M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | WNW | XRTX |
|---|---|---|
| Price | $4.30 | $2.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 1.8M |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.35 |
| 52 Week High | $13.52 | $3.60 |
Technical Indicators
Market Signals| Indicator | WNW | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 66.05 |
| Support Level | $1.27 | $0.52 |
| Resistance Level | $5.43 | $3.00 |
| Average True Range (ATR) | 0.93 | 0.30 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 43.65 | 47.40 |
Price Performance
Historical ComparisonAbout WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.